Literature DB >> 1424040

Fenestrated Fontan with delayed catheter closure. Effects of volume loading and baffle fenestration on cardiac index and oxygen delivery.

C Mavroudis1, V R Zales, C L Backer, A J Muster, L A Latson.   

Abstract

BACKGROUND. The fenestrated Fontan operation has been applied to high-risk patients with univentricular hearts, resulting in improved survival. The purpose of this study was to determine the hemodynamic factors responsible for these improved results. METHODS AND RESULTS. We performed the fenestrated Fontan operation in 17 high-risk patients with univentricular hearts (median age, 3 years; age range, 1.2-25 years). High-risk characteristics were depressed ventricular function and/or hypertrophy (n = 12), atrioventricular valve insufficiency (n = 5), pulmonary artery distortion (n = 6), elevated pulmonary vascular resistance (> 2 units/m2) (n = 4), previously failed Fontan operation (n = 2), or associated Wolff-Parkinson-White syndrome (n = 1). Intraoperative hemodynamic measurements (n = 8) included cardiac index (by aortic flow probe), peripheral arterial O2 saturations, and left and right atrial pressures during inflow occlusion, followed by volume loading with open versus closed fenestration. Mean baffle fenestration was 3.5 mm (range, 2.7-5.0 mm). Multiple regression analysis (cardiac index versus atrial pressure) revealed cardiac index was greater with open than with closed fenestration (p < 0.001) during volume loading. Oxygen delivery (cardiac index multiplied by oxygen content) was also greater with open than with closed fenestration (p < 0.001). Survival was 100% with a mean follow-up of 10.4 months; pleural drainage was high in two patients. Subsequent transcatheter fenestration closure resulted in increased O2 saturation (87 +/- 1% to 96 +/- 0.3%, p < 0.05). CONCLUSIONS. The fenestrated Fontan operation improves survival in high-risk patients by increasing cardiac index and maintaining oxygen delivery, despite mild arterial O2 desaturation. Subsequent transcatheter fenestration closure can be performed after hemodynamic assessment.

Entities:  

Mesh:

Year:  1992        PMID: 1424040

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Closure of external tunnel Fontan fenestration: a novel use of the Amplatzer vascular plug.

Authors:  Makram R Ebeid; Inder Mehta; Charles H Gaymes
Journal:  Pediatr Cardiol       Date:  2008-08-19       Impact factor: 1.655

2.  Fenestration in extracardiac conduits in children after modified Fontan operation by implantation of stent grafts.

Authors:  I Michel-Behnke; M Luedemann; J Bauer; K-J Hagel; H Akintuerk; D Schranz
Journal:  Pediatr Cardiol       Date:  2005 Jan-Feb       Impact factor: 1.655

3.  Creation and enlargement of atrial defects in congenital heart disease.

Authors:  G R Veldtman; G Norgard; H Wåhlander; Y Garty; O Thabit; B W McCrindle; K J Lee; L N Benson
Journal:  Pediatr Cardiol       Date:  2005 Mar-Apr       Impact factor: 1.655

4.  Occlusion of Fontan fenestrations using Amplatzer septal occluder.

Authors:  Amira A A H Al-Hay; Lulu Abushaban; Mustafa A Al-Qbandi; Muath Alanbaei
Journal:  Int J Cardiovasc Imaging       Date:  2010-09-22       Impact factor: 2.357

5.  Long-term results of the fenestrated Fontan operation. Progress of patients with patent fenestrations.

Authors:  M Takeda; M Shimada; A Sekiguchi; A Ishizawa
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-09

6.  Transcatheter closure of fenestration with detachable coils after the Fontan operation.

Authors:  Sung Hye Kim; I-Seok Kang; June Huh; Heung Jae Lee; Ji-Hyuk Yang; Tae-Gook Jun
Journal:  J Korean Med Sci       Date:  2006-10       Impact factor: 2.153

7.  Fenestration closure with Amplatzer Duct Occluder II in patients after total cavo-pulmonary connection.

Authors:  Sebastian Góreczny; Paweł Dryżek; Gareth J Morgan; Anna Mazurek-Kula; Jacek J Moll; Jadwiga A Moll; Shakeel Qureshi; Tomasz Moszura
Journal:  Arch Med Sci       Date:  2016-11-28       Impact factor: 3.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.